Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Individualized treatment based on pharmacogenomics and organoid drug sensitivity in metastatic colorectal cancer
2020-003395-41Phase 2Active
- Sponsor
- Oslo University Hospital
- Start
- Sep 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alectinib, crizotinib, dasatinib, everolimus, gemcitabine and 12 more in metastatic colon cancer (mCRC), sponsored by Oslo University Hospital. Started Sep 2020; status: active.
02
Drugs
alectinibcrizotinibdasatinibeverolimusgemcitabine
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on 2020-003395-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003395-41.